Monoclonal Antibodies in Cancer Therapy

Author(s)	Taif Iqbal, Piyush Choudhary, Kashif Raza
Country	India
Abstract	In recent years, there have been significant advancements in cancer treatment, particularly with the use of Monoclonal Antibodies (mAbs). These targeted therapies have shown promise in managing different types of cancer with fewer side effects due to their high specificity. They have become a predominant category of newly developed drugs. Monoclonal antibodies offer diverse mechanisms of action and can directly target cancer cells while also boosting long-lasting anti-tumor immune responses. This versatility has led to the development of innovative cancer treatment strategies. The use of monoclonal antibody drugs has grown rapidly, with FDA approval for various diseases, including cancer, autoimmune disorders, metabolic conditions, and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the FDA, but there is still room for expansion in this field.
Keywords	Monoclonal antibodies ,cancer, Immunotherapy, therapeutic antibodies, Tumor cells
Published In	Volume 5, Issue 5, September-October 2023
Published On	2023-09-24
Cite This	Monoclonal Antibodies in Cancer Therapy - Taif Iqbal, Piyush Choudhary, Kashif Raza - IJFMR Volume 5, Issue 5, September-October 2023. DOI 10.36948/ijfmr.2023.v05i05.6242
DOI	https://doi.org/10.36948/ijfmr.2023.v05i05.6242
Short DOI	https://doi.org/gssfqq

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research